Tranilast Enhances the Anti-tumor Effects of Tamoxifen on Human Breast Cancer Cells in Vitro

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2013 Oct 23

PMID 24143895

Citations 13

Authors

Sara Darakhshan

Ali Ghanbari

Affiliations

Soon will be listed here.

Abstract

Background: Tamoxifen is the most widely used anti-estrogen for the treatment of breast cancer. Studies show that the combination therapy with other substances that helps the activity of tamoxifen. The objective of this study was to evaluate the effect of tamoxifen when used in combination with tranilast on human breast cancer cells.

Results: Two MCF-7 and MDA-MB-231 human breast cancer cell lines were treated with tamoxifen and/or tranilast. The cell viability and cytotoxicity was assessed using MTT and LDH assays; the apoptotic effects were examined by TUNEL assay, acridine orange/ethidium bromide staining and DNA laddering, also the expression levels of bax and bcl-2 genes were detected by real-time RT-PCR. The mRNA expression of TGF-β ligands and receptors examined using real-time RT-PCR and TGF-β1 protein secretion levels were also evaluated by ELISA assay. Inhibitory effect of these drugs on invasion and metastasis were tested by wound healing and matrigel invasion assay.

Conclusions: These findings indicate that tranilast, by synergistic effect, enhances the activity of tamoxifen and the TGF-β pathway is a target for this combination therapy, therefore; we propose that this combined treatment may be suitable selection in prevention of breast cancer.

Citing Articles

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast.

Ochi K, Suzawa K, Thu Y, Takatsu F, Tsudaka S, Zhu Y Cancer Sci. 2022; 113(10):3428-3436.

PMID: 35871750 PMC: 9530873. DOI: 10.1111/cas.15502.

Teucrium polium Extract Enhances the Anti-Angiogenic Effect of Tranilast in a Three-Dimensional Fibrin Matrix Model.

Sheikhbahaei F, Nematollahi-Mahani S, Khazaei M, Khazaei M, Khazayel S Asian Pac J Cancer Prev. 2021; 22(8):2471-2478.

PMID: 34452560 PMC: 8629455. DOI: 10.31557/APJCP.2021.22.8.2471.

The Role of Desmoplasia and Stromal Fibroblasts on Anti-cancer Drug Resistance in a Microengineered Tumor Model.

Saini H, Eliato K, Silva C, Allam M, Mouneimne G, Ros R Cell Mol Bioeng. 2019; 11(5):419-433.

PMID: 31719892 PMC: 6816733. DOI: 10.1007/s12195-018-0544-9.

Hypoxia-induced HIF-1α and ZEB1 are critical for the malignant transformation of ameloblastoma via TGF-β-dependent EMT.

Yoshimoto S, Tanaka F, Morita H, Hiraki A, Hashimoto S Cancer Med. 2019; 8(18):7822-7832.

PMID: 31674718 PMC: 6912026. DOI: 10.1002/cam4.2667.

Repurposing of Tranilast for Potential Neuropathic Pain Treatment by Inhibition of Sepiapterin Reductase in the BH Pathway.

Moore B, Islam B, Ward S, Jackson O, Armitage R, Blackburn J ACS Omega. 2019; 4(7):11960-11972.

PMID: 31460307 PMC: 6682008. DOI: 10.1021/acsomega.9b01228.

References

Adams J, Cory S . The Bcl-2 protein family: arbiters of cell survival. Science. 1998; 281(5381):1322-6. DOI: 10.1126/science.281.5381.1322. View

Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K . Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Prostate. 2009; 70(3):229-38. DOI: 10.1002/pros.21056. View

Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y . Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med. 2009; 217(3):193-201. DOI: 10.1620/tjem.217.193. View

Rajput S, Prashanth Kumar B, Sarkar S, Das S, Azab B, Santhekadur P . Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One. 2013; 8(4):e61342. PMC: 3629226. DOI: 10.1371/journal.pone.0061342. View

Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, UJIIE A . Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis. 1995; 118(2):213-21. DOI: 10.1016/0021-9150(95)05607-6. View

Renvoize C, Biola A, Pallardy M, Breard J . Apoptosis: identification of dying cells. Cell Biol Toxicol. 1998; 14(2):111-20. DOI: 10.1023/a:1007429904664. View

Colletta A, Wakefield L, Howell F, Danielpour D, Baum M, Sporn M . The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest. 1991; 87(1):277-83. PMC: 295044. DOI: 10.1172/JCI114983. View

Shi X, Miao S, Wu Y, Zhang W, Zhang X, Ma H . Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int J Mol Sci. 2013; 14(8):15655-68. PMC: 3759878. DOI: 10.3390/ijms140815655. View

Renoir J, Bouclier C, Seguin A, Marsaud V, Sola B . Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J Mol Endocrinol. 2008; 40(3):101-12. DOI: 10.1677/JME-07-0143. View

10.

Buck M, Pfizenmaier K, Knabbe C . Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Mol Endocrinol. 2004; 18(7):1643-57. DOI: 10.1210/me.2003-0278. View

11.

Gavrieli Y, Sherman Y, Ben-Sasson S . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992; 119(3):493-501. PMC: 2289665. DOI: 10.1083/jcb.119.3.493. View

12.

Fukuyama J, Miyazawa K, Hamano S, UJIIE A . Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol. 1996; 74(1):80-4. View

13.

Hata A, Shi Y, Massague J . TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today. 1998; 4(6):257-62. DOI: 10.1016/s1357-4310(98)01247-7. View

14.

Fleisch M, Maxwell C, Barcellos-Hoff M . The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer. 2006; 13(2):379-400. DOI: 10.1677/erc.1.01112. View

15.

Stewart B . Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst. 1994; 86(17):1286-96. DOI: 10.1093/jnci/86.17.1286. View

16.

Johnstone R, Ruefli A, Lowe S . Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108(2):153-64. DOI: 10.1016/s0092-8674(02)00625-6. View

17.

Gorsch S, Memoli V, Stukel T, Gold L, Arrick B . Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992; 52(24):6949-52. View

18.

Basolo F, Fiore L, Ciardiello F, Calvo S, Fontanini G, Conaldi P . Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int J Cancer. 1994; 56(5):736-42. DOI: 10.1002/ijc.2910560521. View

19.

Prashanth Kumar B, Rajput S, Dey K, Parekh A, Das S, Mazumdar A . Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer. 2013; 13:273. PMC: 3681557. DOI: 10.1186/1471-2407-13-273. View

20.

Elliott R, Blobe G . Role of transforming growth factor Beta in human cancer. J Clin Oncol. 2005; 23(9):2078-93. DOI: 10.1200/JCO.2005.02.047. View